ROTH MKM resumed coverage on Lemaitre Vascular with a new price target
$LMAT
Medical/Dental Instruments
Health Care
ROTH MKM resumed coverage of Lemaitre Vascular with a rating of Buy and set a new price target of $100.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/6/2025 | $95.00 | Mkt Perform → Outperform | Barrington Research |
| 2/28/2025 | Outperform → Perform | Oppenheimer | |
| 2/28/2025 | Outperform → Mkt Perform | Barrington Research | |
| 2/13/2025 | $95.00 | Equal Weight | Wells Fargo |
| 10/15/2024 | $96.00 | Neutral | Cantor Fitzgerald |
| 8/2/2024 | $85.00 → $105.00 | Buy | Lake Street |
| 5/31/2024 | $100.00 | Buy | ROTH MKM |
| 4/26/2024 | $59.00 → $75.00 | Hold → Buy | Stifel |
4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)
4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)
4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)
Barrington Research upgraded Lemaitre Vascular from Mkt Perform to Outperform and set a new price target of $95.00
Oppenheimer downgraded Lemaitre Vascular from Outperform to Perform
Barrington Research downgraded Lemaitre Vascular from Outperform to Mkt Perform
BURLINGTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q2 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q2 2025: Sales $64.2mm, +15% (+15% organic)Gross margin 70.0%, +110 bpsOp. income $16.1mm, +12%Op. margin 25%Earnings per diluted share $0.60, +16%Cash up $16.9mm sequentially to $319.5mm Catheters (+27%) and grafts (+19%) drove Q2 sales growth. EMEA sales increased 23%, Americas 12%, and APAC 12%. Price accounted for 8% of sales growth and units 7%. Gross margin of 70.0% (vs. 68.9% in Q2 2024) increased due to higher average selling prices
BURLINGTON, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at ir.lemaitre.com. About LeMaitre LeMaitre is a provider of devices, implants, and services fo
MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. "On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company" commented John Seaberg, Chairman o
144 - LEMAITRE VASCULAR INC (0001158895) (Subject)
10-Q - LEMAITRE VASCULAR INC (0001158895) (Filer)
8-K - LEMAITRE VASCULAR INC (0001158895) (Filer)
MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. "On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company" commented John Seaberg, Chairman o
GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. "JJ" Pellegrino, Jr. to its Board of Directors. Mr. Pellegrino, who will also serve as Chairman of the Board's Audit Committee, brings decades of operational and financial experience as well as an extensive knowledge of the medical device industry to the board. Mr. Pellegrino most recently served as Chief Financial Officer of LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of devices, implants and services for the treatm
Bridget Ross brings extensive experience in MedTech development and services;Joins advisory board of healthcare, logistics, capital markets and innovation leaders VANCOUVER, BC, March 23, 2021 /PRNewswire/ - Maitri Health Technologies Corp. ("Maitri") (CSE: MTEC) (FRA: D84), a global platform for healthcare supply security, today announced the appointment of Bridget Ross to its Advisory Board. Ms. Ross is currently CEO of ChroniSense Medical, Ltd., an Israel-based MedTech company and maker of wearable, medical-grade disease management devices. Ms. Ross serves as a Board Director for LeMaitre Vascular Inc. (NASDAQ: LMAT) and as a mentor for early stage MedTech companies through MassMEDIC and
SC 13G - LEMAITRE VASCULAR INC (0001158895) (Subject)
SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)
SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)
BURLINGTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q2 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q2 2025: Sales $64.2mm, +15% (+15% organic)Gross margin 70.0%, +110 bpsOp. income $16.1mm, +12%Op. margin 25%Earnings per diluted share $0.60, +16%Cash up $16.9mm sequentially to $319.5mm Catheters (+27%) and grafts (+19%) drove Q2 sales growth. EMEA sales increased 23%, Americas 12%, and APAC 12%. Price accounted for 8% of sales growth and units 7%. Gross margin of 70.0% (vs. 68.9% in Q2 2024) increased due to higher average selling prices
BURLINGTON, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at ir.lemaitre.com. About LeMaitre LeMaitre is a provider of devices, implants, and services fo
BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q1 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q1 2025: Sales $59.9mm, +12% (+13% organic)Gross margin 69.2%, +60 bpsOp. income $12.6mm, +6%Op. margin 21%Earnings per diluted share $0.48, +10%Cash up $2.8mm sequentially to $302.5mm Grafts (+17%) and carotid shunts (+14%) drove sales growth. EMEA sales increased 18%, Americas 11%, and APAC 3%. Gross margin was 69.2% (vs. 68.6% in Q1 2024), due to higher average selling prices and manufacturing efficiencies. Operating income of $12.6mm wa